AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Biopharmadive

Published November 10, 2026

London biotech Oyster harvests $60M for tau-targeting brain drugs | BioPharma Dive

Read the full story at Biopharmadive

psychedelic brain Aug. 12, 2026. Psychedelics developer Definium scores more positive data for LSD pill · A headshot of Kabir Nath, CEO of Compass.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech